z-logo
open-access-imgOpen Access
Activity of Cysteamine against the Cystic Fibrosis Pathogen Burkholderia cepacia Complex
Author(s) -
Douglas FraserPitt,
Derry K. Mercer,
Emma Lovie,
Jennifer Robertson,
Deborah A. O′Neil
Publication year - 2016
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.01198-16
Subject(s) - cysteamine , microbiology and biotechnology , burkholderia cepacia complex , cystic fibrosis , antibiotics , biofilm , aminoglycoside , burkholderia , bacteria , pseudomonas aeruginosa , burkholderia cenocepacia , biology , chemistry , biochemistry , genetics
There are no wholly successful chemotherapeutic strategies against Burkholderia cepacia complex (BCC) colonization in cystic fibrosis (CF). We assessed the impact of cysteamine (Lynovex) in combination with standard-of-care CF antibiotics in vitro against BCC CF isolates by the concentration at which 100% of bacteria were killed (MIC100) and checkerboard assays under CLSI standard conditions. Cysteamine facilitated the aminoglycoside-, fluoroquinolone- and folate pathway inhibitor-mediated killing of BCC organisms that were otherwise resistant or intermediately sensitive to these antibiotic classes. Slow-growing BCC strains are often recalcitrant to treatment and form biofilms. In assessing the impact of cysteamine on biofilms, we demonstrated inhibition of BCC biofilm formation at sub-MIC100s of cysteamine.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom